Pharmaceuticals

Global Gastric Antisecretory Drug Market Projected to Expand at 5.8% CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Gastric Antisecretory Drug Market Size Likely To Evolve From 2025 Through 2034?

The gastric antisecretory drug market has seen substantial growth in recent years. It is projected to expand from $14.87 billion in 2024 to $15.63 billion in 2025, at a compound annual growth rate (CAGR) of 5.1%. This historic market expansion can be linked to factors such as increasing stress levels and sedentary lifestyles, a rise in helicobacter pylori infections, supportive government healthcare policies, the growth of medical tourism, and the proliferation of e-commerce and online pharmacies.

The gastric antisecretory drug market is anticipated to experience substantial expansion over the coming years, reaching $19.56 billion by 2029 with a compound annual growth rate (CAGR) of 5.8%. This projected growth is fueled by factors such as the increasing incidence of gastrointestinal conditions, an expanding elderly demographic, heightened understanding of digestive wellness, improvements in healthcare infrastructure, and the greater intake of fast and processed foods. Key trends during this period are expected to encompass the extensive use of NSAIDs, the widespread over-the-counter (OTC) accessibility of antisecretory medications, innovations in drug delivery mechanisms, the availability of generic versions of drugs, and progress in combination treatment approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24222&type=smp

What Are The Main Drivers Boosting The Gastric Antisecretory Drug Industry’s Expansion?

An anticipated rise in the occurrence of gastrointestinal disorders is projected to fuel the expansion of the gastric antisecretory drug market in the coming years. These conditions affect the digestive system, including the stomach, intestines, and associated organs, resulting in symptoms such as pain, bloating, and altered bowel movements. The escalation in gastrointestinal disorders is primarily attributed to poor dietary habits, with excessive consumption of processed foods and insufficient fiber leading to imbalances in gut microbiota and compromised digestion. Gastric antisecretory drugs are essential because an excess of stomach acid can damage the protective lining of the gastrointestinal tract, causing irritation or injury, which these medications help prevent by reducing acid production. For example, in May 2025, a report published by ScienceDirect, a US-based bibliographic database, revealed that roughly 23.5 million gastrointestinal endoscopies were performed in 2022. Therefore, the increasing prevalence of gastrointestinal disorders will significantly boost the growth of the gastric antisecretory drug market.

What Are The Leading Segments Analyzed In The Gastric Antisecretory Drug Market?

The gastric antisecretory drug market covered in this report is segmented –

1) By Drug Class: Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Antacids, Prostaglandin Analogs

2) By Route Of Administration: Oral, Intravenous, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Other Applications

Subsegments:

1) By Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole

2)By H2 Receptor Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine

3) By Antacids: Magnesium Hydroxide, Calcium Carbonate, Aluminum Hydroxide, Sodium Bicarbonate, Combination Antacids

4) By Prostaglandin Analogs: Misoprostol, Enprostil

Which Market Trends Are Creating New Opportunities In The Gastric Antisecretory Drug Industry?

Leading companies in the gastric antisecretory drug market are concentrating on developing advanced products, such as antisecretory compounds, to offer more enduring relief. These antisecretory compounds are substances designed to diminish or prevent the secretion of bodily fluids, particularly gastric acid, by influencing specific cellular pathways or receptors. For example, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical company, unveiled Rabeprazole + Levosulpiride SR Capsules, a new formulation tailored for Gastrointestinal patients. This innovative formulation uniquely brings together rabeprazole sodium, a powerful antisecretory agent that specifically inhibits the H?/K? ATPase in gastric parietal cells, and levosulpiride, recognized for its central antidopaminergic and antiemetic characteristics. Each capsule delivers 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, which ensures focused and extended therapeutic action. Its dual approach effectively addresses both acid reduction and the regulation of gastrointestinal motility.

Which Key Market Players Are Investing In Expansion And Innovation Of Gastric Antisecretory Drug Market?

Major companies operating in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastric-antisecretory-drug-global-market-report

How Is Gastric Antisecretory Drug Market Demand Varying Across Different Regions?

North America was the largest region in the gastric antisecretory drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric antisecretory drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastric Antisecretory Drug Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24222&type=smp

Browse Through More Reports Similar to the Global Gastric Antisecretory Drug Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795